> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vertex Signal Inhibitor VX-993 Misses Trial Goal
- URL: https://www.fdaweb.com/vertex-signal-inhibitor-vx-993-misses-trial-goal/
- Published: 2025-08-05T12:00:00.000Z
- Updated: 2026-09-14T15:18:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159630

Vertex Pharmaceuticals says its investigational selective NaV1.8 pain signal inhibitor VX-993 did not meet the primary endpoint in a Phase 2 study evaluating its safety and effectiveness in treating acute pain after bunionectomy surgery. As a result, a company [statement](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-vx-993-treatment-acute?ref=fdaweb.com) says, VX-993 will not be moved into pivotal development as monotherapy in acute pain.

Company officials indicated that VX-993 was not expected to be superior to Vertex’ existing NaV1.8 inhibitors, based on the trial results.

The statement says that VX-993 was generally safe and well-tolerated at all doses studied in the Phase 2 trial, with the overall incidence of adverse events similar to placebo.